It is not medical advice, and FlexPeptides does not sell products intended for human consumption.
CJC-1295 is a modified analog of growth-hormone-releasing hormone (GHRH), the hormone the hypothalamus normally uses to tell the pituitary to release GH
Trial evidence: Tesamorelin 2mg SC daily sustained GH/IGF-1 elevation, 15-18% visceral fat reduction over 6 months (Falutz, NEJM 2007, PMID 17699044) Ipamorelin 200-300 mcg peak GH 5-10x baseline within 30 minutes, no cortisol/prolactin bump (Raun, EJE 1998, PMID 9539826) GHRH + GHRP synergy 2-3x greater amplitude than either alone (Bowers, JCEM 1991, PMID 2004615) Community protocols extend this evidence base with cycling patterns that weren't studied in the original trials the 5-on/2-off rhythm and 8-week cycles are empirical community consensus, not clinically validated
Growth-hormone secretagogues including GHRH and its analogs such as CJC-1295, and growth-hormone-releasing peptides (GHRPs) such as Ipamorelin are prohibited at all times under section S2 of the WADA Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics)
A Cochrane review included 55 completed observational studies mostly with a nested case-control design published over three decades (67)
